Press Releases
ORLANDO, FL, October 8, 2013 – At the North American Spine Society (NASS) meeting October 9 – 12 in New Orleans, Mazor Robotics will exhibit and highlight the clinical experience with Renaissance® Guidance System since its debut at NASS 2011. In addition to Renaissance’s contribution to reaching the 5,000 case/35,000 implant milestones for Mazor Robotics, the past 24 months have included clinical experiences with Mazor Robotics technology being reported in podium presentations and peer-reviewed journals.
Mazor Robotics will be located at booth #1539 in the NASS exhibit hall in New Orleans. Opportunities to speak with experienced Renaissance surgeons will be available during the meeting, as well as the ability to participate in a surgeon-led workshop on Friday and a hands-on lab with Renaissance on Saturday. Neurosurgeons attending NASS will also be able to learn more about the recent clinical experience with the brain application of the system.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
David Schemelia – Media
646.201.5431
Latest Tweet
Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf… https://t.co/LJDbcI17O1